Successful alternative vaccination with BNT162b2 mRNA COVID-19 vaccine for new-onset IgA vasculitis after receiving mRNA-1273-case report.

Morioka, Fumiyuki; Nakatani, Shinya; Tsuda, Akihiro; Mori, Katsuhito; Emoto, Masanori

Morioka, Fumiyuki; Nakatani, Shinya; Tsuda, Akihiro; Mori, Katsuhito; Emoto, Masanori.

Afiliação

Morioka F; Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.
Nakatani S; Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. nakatani-s@omu.ac.jp.
Tsuda A; Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Mori K; Department of Nephrology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Emoto M; Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.

CEN Case Rep ; 11(4): 511-512, 2022 11.

Article em En | MEDLINE | ID: mdl-36114985

Assuntos

COVID-19; Vasculite por IgA; Humanos; Vacina de mRNA-1273 contra 2019-nCoV; Vacina BNT162; Vacinas contra COVID-19; RNA Mensageiro; Vacinação

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vasculite por IgA / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google